Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02159027 · ClinicalTrials.gov registry record · Phase 2
Maraviroc and NeuroAIDS Pathogenesis
A Phase 2 study, sponsored by University of Hawaii.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
NCT02159027 is a Phase 2 study that has completed, run by University of Hawaii. The registered enrollment target is 48 participants.
The verdict
NCT02159027, a Phase 2 study, has completed, sponsored by University of Hawaii.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
Study Summary
Maraviroc is an antiretroviral medication that may help in improving mental function in HIV infected patients with mental problems by decreasing inflammatory tendencies. We will test this in a clinical trial of 42 HIV infected individuals with some mild to moderate mental problems who are already on HIV medications and doing well. We will add Maraviroc or a sugar pill to their HIV medications and see if mental function improves over 48 weeks. This study will be conducted at 2 sites in Hawaii and Puerto Rico.
Interventions
- DRUG Placebo
- DRUG Maraviroc
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2015-06 |
| Est. Completion | 2019-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02159027
The ClinicalTrials.gov registry entry for NCT02159027 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Hawaii, which has 77 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02159027 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02159027 about?
NCT02159027 is a clinical study titled "Maraviroc and NeuroAIDS Pathogenesis". Maraviroc is an antiretroviral medication that may help in improving mental function in HIV infected patients with mental problems by decreasing inflammatory tendencies. We will test this in a clinical trial of 42 HIV infected individuals with some mild to moderate mental problems who are already on...
What is the current status of trial NCT02159027?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2015-06. Estimated completion is 2019-02.
What interventions are being tested in trial NCT02159027?
The interventions under investigation include: Placebo (DRUG), Maraviroc (DRUG).
Who is sponsoring clinical trial NCT02159027?
This trial is sponsored by University of Hawaii, which has 77 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.